Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. Giovannoni G, Radue E-W, Havrdova E, Riester K, Greenberg S, Mehta L, Elkins J J Neurol. 2013 Dec 29. PMID: 24375015. Abstract CommentRecommendBookmarkWatch
